Nanoparticles for tumor-specific intracellular drug delivery.
Nanoparticles for tumor-specific intracellular drug delivery.
复制标题
用于肿瘤特异性细胞内药物输送的纳米颗粒。
DOI：
10.1109/iembs.2009.5334835
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Xu,Peisheng
中科院分区：
文献类型：
--
作者：
Yeo,Yoon;Xu,Peisheng
虽然卵巢癌的腹膜内（IP）治疗在理论上是一种有前途的治疗选择，但由于IP药物递送的几个挑战，它在临床上并不被广泛接受。纳米粒是一种很有前途的药物载体，有望缓解IP化疗的困难。然而，目前可用的纳米颗粒需要进一步改进以满足以下要求：（i）它们必须保持与正常细胞的非相互作用，并防止有效载荷过早泄漏;（ii）一旦药物载体到达肿瘤，它们应该有效地进入细胞并在细胞中释放药物以有效地杀死靶细胞。我们最近的观察表明，一种流行的纳米颗粒系统在很大程度上辜负了这些期望。为了安全有效的IP化疗，迫切需要新型载体和/或表面修饰策略。
While intraperitoneal (IP) therapy of ovarian cancer is a theoretically promising treatment option, it is not clinically well accepted due to the several challenges in IP drug delivery. Nanoparticles are promising drug carriers, which may alleviate the difficulties in IP chemotherapy. However, currently available nanoparticles need to be further improved to fulfill the following requirements: (i) they must remain non-interactive with normal cells and prevent the payload from premature leaking; (ii) once the drug carriers reach the tumor, they should enter the cells efficiently and release the drug in the cells to effectively kill the targeted cells. Our recent observation indicates that a popular nanoparticle system fails these expectations by large margin. For safe and effective IP chemotherapy, new types of carriers and/or surface modification strategies are urgently needed.